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Introduction {#s1}
============

The human immunodeficiency virus (HIV) is one of the most life threatening infections of this century ([@R1],[@R2]). Acquired immune deficiency syndrome (AIDS) is a systemic consequence of HIV infection, and it is characterized by severe disorders and progressive damage of immune responses.^1^Estimates by the World Health Organization (WHO) indicate that more than 2 million people have become newly infected with HIV and nearly 2 million AIDS-related deaths occur per year ([@R3]). Moreover, estimates from UNAIDS have suggested that more than 90,000 HIV infected individuals are living in Iran ([@R4]).

Antiretroviral therapy (ART) is the use of drugs to treat infection by retroviruses ([@R5]). Typically, the combination of three or four antiretroviral drugs is known as highly active antiretroviral therapy (HAART) and is offered as a standard treatment to manage HIV infection ([@R6],[@R7]). The advent of HAART has dramatically changed the course of HIV infection and led to an improvement in HIV patients\' quality of life ([@R8]). In addition to all the benefits, HAART may have numerous side effects and toxicities ([@R6]). Hematological abnormalities are common complications in HIV infected patients ([@R9]). The side effects of antiretroviral drugs are common causes of the abnormalities associated with the increased risk of mortality rate ([@R6],[@R10]).

Micronutrient deficiencies such as those of vitamin B12 and folic acid are common among HIV infected individuals and are associated with prolonged treatment ([@R10],[@R11]). Individuals with micronutrient deficiencies are commonly at higher risk of AIDS disease progression and mortality ([@R12]). Moreover, these deficiencies may intensify the antiretroviral drugs related hematological abnormalities ([@R13],[@R14]). Vitamins can be a useful modulator to fix hematologic adverse changes caused by antiretroviral drugs ([@R11],[@R12],[@R14]).

Anemia is a frequently observed disorder among HIV infected patients, which worsens the consequence of HIV disease and decreases CD4 cells counts ([@R10]). Few studies aimed to determinate the impact of micronutrient on hematological abnormalities of HIV infected patients after antiretroviral therapy. Therefore, we aimed to assess the impact of short-term treatment of vitamin B12 and folic acid combination on hematological parameters of HIV infected patients receiving HAART in Shiraz, southwest of Iran.

Methods {#s2}
=======

Study Design, Setting and Population {#s2-1}
------------------------------------

This was a cross-sectional study conducted on 100 confirmed HIV positive patients who referred to Shiraz HIV/AIDS research center; this center is the second HIV/AIDS research center in Iran and is affiliated to Shiraz University of Medical Sciences. All included patients were at AIDS stage with CD4+ lymphocyte counts ≤200μl Cells/mm ([@R3]). The study population consisted of 100 volunteer HIV patients who were selected based on convenience sampling. All participants initiated ART treatment at least three months before the study and whose rate of adherence was higher than 90%. The first-line of HAART regimen contained a fixed-dose of Zidovudine (300mg), Lamivudine (950mg), and Efavirenz (600mg). The studied population received one capsule containing 100µg vitamin B12 weekly and 5mg folic acid, administered daily.

This study was in accordance with the declaration of Helsinki, and an informed written consent was taken from all the participants.

Assessing HIV and Hematological Parameters {#s2-2}
------------------------------------------

An HIV seropositive patient was primarily diagnosed by the enzyme linked immunosorbent assay (ELISA) (Dia. Pro Diagnostic Bioprobes, Italy) and subsequently primary positive ELISA results were confirmed by a Western Blot test. Two blood samples, once before the initiation of vitamin treatment and once more after vitamins treatment was performed for the participants. In addition, baseline hematological parameters were obtained from the patients' recorded data from Shiraz HIV/AIDS research center database. Hematological parameters, e.g., hemoglobin (Hb), mean corpuscular volume (MCV), white blood cells (WBCs) were determined using BC-3000 MINDRAY automated hematology analyzer (Mindray, China). Moreover, demographic and clinical information including age, gender and transmission route were collected using a pretested structured questionnaire through interviews and reviewing the medical records.

Statistical analysis was performed using SPSS^TM^ software, Version 21.0 (IBM Corp., Armonk, NY, USA) and paired t-tests was used to analyze the results. p\<0.05 was considered as statistically significant.

Results {#s3}
=======

Demographic Data {#s3-1}
----------------

Of the 100 participants, 54% and 46% were female and male, respectively. The overall mean±SD age was 37.8 ±11.7 years, within the age range of 4-64 years. The common HIV transmission route in infected patients was infected husband (37%), followed by intravenous drug use (27%).

HAART Effect on Hematological Parameters {#s3-2}
----------------------------------------

Overall, after at least six months of receiving antiretroviral therapy with adherence above 90%, the patients showed an increase in the mean of Hb, hematocrit (HCT), MCV, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelets (PLT), and total leukocyte count (TLC) compared to the baseline parameters. However, the observed differences were statistically significant only in MCV, MCH, HCT, and TLC (p\<0.05). While there was a decrease in the status of red cell distribution width (RDWCV), red blood cells (RBCs) and WBC compared to baseline, the differences were significant only in RBC (4.6±3.1 to 3.9±0.8x10^6^/µL, p\<0.03). There were different patterns of hematological effects of HAART on MCHC, RDWCV and WBC status between female and male patients, but the difference did not reach statistical significance ([Table 1](#T1){ref-type="table"}).

###### The hematological characteristics of the study population in baseline, on HAART and after vitamins treatment

  -------------------- ------------- --------------- --------------- ------------ ---------------- ------------
  Studied factors      Male status   p               Female status   p            Overall status   p
  Hb (g/dL)                                                                                        
  Baseline Mean ± SD   12.2±2.5                      11.6±2.7                     11.9±2.6         
  On HAART Mean ± SD   12.6±2.7      p= 0.2783^a^    12.1±1.7        p= 0.1187    12.3±2.6         p= 0.2780
  Vitamins Mean ± SD   12.9±2.1      p= 0.3815 ^b^   12.2±1.5        p= 0.6596    12.5±1.8         p= 0.5278
  HCT (%)                                                                                          
  Baseline Mean ± SD   36.4±7.1                      34±4.8                       35.1±6.1         
  On HAART Mean ± SD   39.3±5.8      p= 0.0018       36.4±5          p= 0.0007    37.8±5.6         p= 0.0013
  Vitamins Mean ± SD   39.3±5.5      p= 1.0000       37.9±4          p= 0.0201    38.6±4.8         p= 0.2794
  MCV (fL)                                                                                         
  Baseline Mean ± SD   81±16.2                       77.5±8.6                     79.1±12.7        
  On HAART Mean ± SD   104.2± 20.5   p\< 0.0001      99.6± 14        p\< 0.0001   101.7± 17.4      p\< 0.0001
  Vitamins Mean ± SD   98.4±14.7     p= 0.0225       95.6±13.3       p= 0.0396    96.9±13.9        p= 0.0323
  MCH (Pg)                                                                                         
  Baseline Mean ± SD   29±5.5                        26.3±4.2                     27.6±5           
  On HAART Mean ± SD   33.2± 5.4     p\< 0.0001      31.7± 5.2       p\< 0.0001   32.4± 5.3        p\< 0.0001
  Vitamins Mean ± SD   32.3±5.8      p= 0.2575       31.2±5.2        p= 0.4974    31.7±5.5         p= 0.3605
  MCHC (g/dL)                                                                                      
  Baseline Mean ± SD   33±3.8                        32.1±3.8                     32.5±3.9         
  On HAART Mean ± SD   32.2±5.4      p= 0.2271       33±2.8          p= 0.0580    32.6±4.2         p= 0.8617
  Vitamins Mean ± SD   33.2±7.4      p= 0.2763       31.8±4          p= 0.0148    32.4±5.8         p= 0.7803
  RDWCV (%)                                                                                        
  Baseline Mean ± SD   13.6±1.4                      15.3±8.3                     14.5±6.2         
  On HAART Mean ± SD   14.1 ±2.2     p= 0.0566       13.7 ±1.8       p= 0.0610    13.9 ±2          p= 0.3582
  Vitamins Mean ± SD   13.9±2.5      p= 0.5488       13.5±1.3        p= 0.3688    13.7±2           p= 0.4803
  PLT (x10 ^3^ /µL)                                                                                
  Baseline Mean ± SD   185.9±93.8                    253.2±130.1                  222.2±119.2      
  On HAART Mean ± SD   194.9±78.8    p= 0.4634       257.8±87.4      p= 0.7695    228.6±88.9       p= 0.6674
  Vitamins Mean ± SD   205.6±84.6    p= 0.3558       291.9±103.6     p= 0.0127    252.2±104.2      p= 0.0864
  RBC (x10 ^6^ /µL)                                                                                
  Baseline Mean ± SD   5±4.5                         4.3±0.9                      4.6±3.1          
  On HAART Mean ± SD   4±0.9         p= 0.0305       3.7±0.7         p\< 0.0001   3.9±0.8          p= 0.0300
  Vitamins Mean ± SD   6.4±3.8       p\< 0.0001      5.6±5.2         p= 0.0004    6±4.6            p\< 0.0001
  WBC (x10 ^3^ /µL)                                                                                
  Baseline Mean ± SD   5±2.2                         4.8±2.1                      4.9±2.1          
  On HAART Mean ± SD   5.2±2         p= 0.5019       4.6±1.7         p= 0.4600    4.9±1.9          p= 1.0000
  Vitamins Mean ± SD   4±2.3         p= 0.0001       4.7±1.8         p= 0.6867    4.3±2.1          p= 0.0354
  TLC (x10 ^3^ /µL)                                                                                
  Baseline Mean ± SD   1.7±1.1                       1.5±0.7                      1.6±0.9          
  On HAART Mean ± SD   2.1±1         p= 0.0077       1.7±0.8         p= 0.0614    1.9±0.9          p= 0.0194
  Vitamins Mean ± SD   2.4±1.4       p= 0.0828       2±1             p= 0.0201    2.2±1.2          p= 0.0469
  -------------------- ------------- --------------- --------------- ------------ ---------------- ------------

a: Baseline status compared with On HAART status, b: On HAART status compared with vitamins status

Vitamins Treatment Effect on Hematological Parameters {#s3-3}
-----------------------------------------------------

After one month of treatment, vitamins in four hematological parameters included Hb, HCT, PLT and TLC, enhancing the effect of HAART, but significant mean changes were observed in TLC from 1.9±0.9 to 2.2±1.2x10^3^/µL. The mean of MCV, MCH and MCHC decreased after vitamins treatment compared to HAART status; this decreasing effect was statistically significant in MCV (101.7± 17.4 to 96.9±13.9fL, p\<0.03). Following the decreasing trend of HAART, RDWCV and WBC mean declined after vitamins treatment, and the differences were statistically significant in WBC (4.9±1.9 to 4.3±2.1x10^3^/µL, p\<0.04). Meanwhile, vitamins significantly adjust decreasing effect of HAART on RBC status (3.9±0.8 to 6±4.6x10^6^/µL, p\<0.001).

Vitamins Treatment Effect vs. Gender {#s3-4}
------------------------------------

Effect of vitamins in some hematological parameters was significantly different between males and females. Among females, HCT mean significantly increased after vitamins treatment compared to HAART status (36.4±5 to 37.9±4%, p\<0.02), while this change was not observed among the male patients. In MCHC, the effect of vitamins on female parameter was opposite of the male, as the MCHC mean significantly decreased in females, but the mean of MCHC increased in males. Vitamins significantly decreased the WBC mean among males (5.2±2 to 4±2.3x10^3^/µL, p\<0.001), while no significant change was observed in females.

Discussion {#s4}
==========

Previously, several benefits of micronutrient supplementation in HIV positive patients have been introduced; namely, increased body weight, improving immune function, reducing inflammation and better hematological status ([@R11],[@R12]). Hematologic toxicity is the common side effect of HIV medications ([@R11],[@R15]). Moreover, HIV infected persons receiving HAART have usually shown lower micronutrient concentrations, and vitamins administration could be a useful adjuster to reduce associated complications of HAART ([@R11]). We compared hematologic parameters among 100 HIV infected patients who had experienced HAART treatment for the first time with Zidovudine, Lamivudine, and Efavirenz before and after vitamin treatment.

The elevation of MCV and depletion of RBC in HAART experienced patients are usually attributed to the adverse effect of Zidovudine, which could explain our findings ([@R16]-[@R18]). In our findings, patients receiving HAART showed a significant increase in TLC and HCT compared to the results at the baseline. In accordance to our findings, Idowu et al. showed a significant increase in TLC and HCT among HIV patients after three months of receiving HAART ([@R19]). Moreover, Florence et al. showed successful treatment with HAART increase TLC status compared to failed treatment patients and stated that the increase in both Hb and TLC compared to baseline could be a good predictor of successful treatment ([@R20]). Another significant hematologic increasing effect of HAART in our results was on MCH; this is consistent with the findings of Gedefaw et al. who showed significant differences of MCH level between HAART experienced and HAART naive participants ([@R21]).

In our study, vitamin B12 and folate treatment during observation period significantly enhanced TLC and RBC parameters compared to HAART status. Previously, in a randomized trial, Haiden et al. showed that combined vitamin B12 and folate administration significantly increased RBC counts in prematureinfants ([@R22]). Moreover, in two separated studies, Tamura et al. and Kim YI et al. indicated the role of vitamin B12 and folate on lymphocyte counts, respectively ([@R23],[@R24]). Linnebanket al. showed that patients with vitamin B12 and folate normal serum levels had lower MCV level compared to those with serum levels below the normal range ([@R25]). Findings of Linnebanket al. are consistent with ours ([@R25]), because after one month of combined vitamins treatment, we observed a significant decrease in MCV mean compared to HAART status.

This study had some limitations. First, because we administrated a combination of B12 and folate, we could not discuss their individual effects. Second, more background factors such as age, digestive disorders and simultaneous infections should have been considered because of their probable effect on vitamins absorption. The final limitation was the lack of assessment of vitamins serum level after administration.

In summary, despite the limitations, combined administration of B12 and folate supplements was a beneficial adjuster on hematologic status of HIV infected patients receiving HAART and can be recommended as a promising therapeutic option against HAART related hematological abnormalities. However, Iranian HIV/AIDS patients with different genetic and lifestyle contexts may have different responses, and to reach a comprehensive conclusion conducting further researches in other parts of the world is highly recommended. Moreover, especial attention should be paid to gender as the effect of vitamins was significantly different on some hematologic parameters between different genders.
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